In view of the pivotal roles of MET in cell growth, proliferation and survival, deregulation of MET signaling has been identified in different types of cancers including thyroid [4], lung [5], breast [6], gastric carcinoma [7], liver [8], colon [9], kidney [10], and ovary [11]. This evidence concerns the gene MET and gastric carcinoma.